American Kidney Fund and IgA Nephropathy Foundation Create New IgA Nephropathy Patient Guidelines

Industry
โดย GlobeNewswire·Read original
Summary · why it matters

The American Kidney Fund and the IgA Nephropathy Foundation have created new patient guidelines for IgA nephropathy, a rare kidney disease. The guidelines are based on recently updated KDIGO clinical practice guidelines and were developed using patient focus group input and clinician review. They provide plain language explanations of the disease, an overview of available treatment options, and practical guidance for discussing treatment with healthcare teams in a printable format. The resource is available on AKF’s website and will be offered in Spanish, Korean, and simplified Chinese, with an interactive version planned for later this year. The effort is part of AKF’s “A Step Ahead of IgA Nephropathy” educational campaign, supported by sponsors including Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical Inc., Travere Therapeutics, Vertex Pharmaceuticals Incorporated, and Calliditas Therapeutics.

Impact on stocks 3

Biotech & Genomic Medicine▲ · 3 stocks
Novartis AG
NOVN
▲ PositiveDemandrelevance

Novartis is a sponsor of the campaign, which could increase patient awareness and demand for its IgA nephropathy treatments.

Travere Therapeutics Inc
TVTX
▲ PositiveDemandrelevance

Travere Therapeutics is a sponsor of the educational campaign, which may increase awareness and demand for its IgA nephropathy treatments.

Vertex Pharmaceuticals Inc
VRTX
▲ PositiveDemandrelevance

Vertex Pharmaceuticals is a sponsor of the educational campaign, potentially boosting awareness and demand for its IgA nephropathy therapies.

Off-coverage companies 1

Calliditas Therapeutics ABPrivate▲ Positive
Demandrelevance

Calliditas Therapeutics is a sponsor of the campaign, potentially driving demand for its IgA nephropathy drug.

© 2026 MarketDXNews